Damora TherapeuticsDMRA
13F holders, Q1 2025 (March 31)11holders +1
3new positions
2sold out
1famous investor
$3.10avg. 13F price*
At the end of Q1 2025, 11 institutions reported holding Damora Therapeutics Inc. (DMRA) in their 13F filings, up 1 from Q4 2024. 3 opened new positions and 2 sold out. The largest holders were Novo Holdings A/S ($310K), Renaissance Technologies ($48K) and Squarepoint Ops LLC ($40K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Damora Therapeutics Inc.
- Filed as
- GALECTO INC (Q1 2025)
- CUSIP
- 36322Q206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $39K |
| Exits | 2 | $931 |
All 13F filers, Q4 2024 → Q1 2025: 13,021 shares bought and 12,382 shares sold, net +639 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Novo Holdings A/S | 0.02% | No change | 99,913 | $310K |
| Renaissance Technologies | 0.00% | Add +2.0% | 15,344 | $48K |
| Squarepoint Ops LLC | 0.00% | Add +2.2% | 12,984 | $40K |
| Susquehanna International Group, LLP | 0.00% | New | 10,722 | $33K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 1,583 | $5K |
| Bank of America Corp. | 0.00% | No change | 1,226 | $4K |
| BlackRock, Inc. | 0.00% | No change | 490 | $2K |
| UBS Group AG | 0.00% | Reduce -97.7% | 285 | $883 |
| Barclays PLC | 0.00% | New | 133 | $412 |
| SBI Securities Co., Ltd. | 0.00% | No change | 18 | $56 |
| Group One Trading LLC | 0.00% | No change | 3 | $9 |
"% of holder's portfolio" is DMRA's weight in each manager's 13F, not the share of Damora Therapeutics Inc. the manager owns.